vir like m6A methyltransferase associatedGenealiases: KIAA1429 · MSTP054 · fSAP121
Q-omics provides the consensus-scored VIRMA profile across patient tissues and cancer cell-line models. VIRMA expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, VIRMA is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, VIRMA protein abundance shows 27,697 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, HNSC, and LSCC as cancer lineages where VIRMA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VIRMA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VIRMA survival associations across molecular data types. VIRMA RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VIRMA RNA expression–survival associations across cancer types. High VIRMA expression shows unfavorable associations in UVM, LIHC, ACC, KIRP and LUSC, but favorable associations in KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for VIRMA RNA expression.
This table summarizes VIRMA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for VIRMA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VIRMA shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRC, LIHC, LUAD and COAD. The HNSC box plot shows higher VIRMA RNA expression in tumor versus normal tissue (log2 FC = +1.213, t-test p < 0.001).
This table shows molecular features associated with VIRMA in patient tissues and cancer cell lines. In patient samples, VIRMA shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, VIRMA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Lymphoma.
